Header Logo

Connection

Patrick Arbuthnot to Genetic Vectors

This is a "connection" page, showing publications Patrick Arbuthnot has written about Genetic Vectors.
Connection Strength

4,539
  1. Hepatic Delivery of Artificial Micro RNAs Using Helper-Dependent Adenoviral Vectors. Methods Mol Biol. 2016; 1364:249-60.
    View in: PubMed
    Score: 0,507
  2. Inhibition of hepatitis B virus replication by helper dependent adenoviral vectors expressing artificial anti-HBV pri-miRs from a liver-specific promoter. Biomed Res Int. 2014; 2014:718743.
    View in: PubMed
    Score: 0,455
  3. Inhibition of HBV replication in vivo using helper-dependent adenovirus vectors to deliver antiviral RNA interference expression cassettes. Antivir Ther. 2014; 19(4):363-73.
    View in: PubMed
    Score: 0,439
  4. Therapeutic potential of adenoviral vectors for delivery of expressed RNAi activators. Expert Opin Drug Deliv. 2010 Dec; 7(12):1373-85.
    View in: PubMed
    Score: 0,355
  5. Inhibition of hepatitis B virus replication with linear DNA sequences expressing antiviral micro-RNA shuttles. Biochem Biophys Res Commun. 2009 Nov 20; 389(3):484-9.
    View in: PubMed
    Score: 0,327
  6. Efficient inhibition of hepatitis B virus replication in vivo, using polyethylene glycol-modified adenovirus vectors. Hum Gene Ther. 2008 Nov; 19(11):1325-31.
    View in: PubMed
    Score: 0,309
  7. Advances with RNAi-Based Therapy for Hepatitis B Virus Infection. Viruses. 2020 08 04; 12(8).
    View in: PubMed
    Score: 0,174
  8. In vitro transcribed mRNA for expression of designer nucleases: Advantages as a novel therapeutic for the management of chronic HBV infection. Adv Drug Deliv Rev. 2021 01; 168:134-146.
    View in: PubMed
    Score: 0,172
  9. In Vivo Delivery of Cassettes Encoding Anti-HBV Primary MicroRNAs Using an Ancestral Adeno-Associated Viral Vector. Methods Mol Biol. 2020; 2115:171-183.
    View in: PubMed
    Score: 0,167
  10. How successful has targeted RNA interference for hepatic fibrosis been? Expert Opin Biol Ther. 2018 04; 18(4):381-388.
    View in: PubMed
    Score: 0,146
  11. ssAAVs containing cassettes encoding SaCas9 and guides targeting hepatitis B virus inactivate replication of the virus in cultured cells. Sci Rep. 2017 08 07; 7(1):7401.
    View in: PubMed
    Score: 0,142
  12. Successful disabling of the 5' UTR of HCV using adeno-associated viral vectors to deliver modular multimeric primary microRNA mimics. J Virol Methods. 2016 09; 235:26-33.
    View in: PubMed
    Score: 0,130
  13. Sustained inhibition of hepatitis B virus replication in vivo using RNAi-activating lentiviruses. Gene Ther. 2015 Feb; 22(2):163-71.
    View in: PubMed
    Score: 0,117
  14. Inactivation of hepatitis B virus replication in cultured cells and in vivo with engineered transcription activator-like effector nucleases. Mol Ther. 2013 Oct; 21(10):1889-97.
    View in: PubMed
    Score: 0,107
  15. Specific micro RNA-regulated TetR-KRAB transcriptional control of transgene expression in viral vector-transduced cells. PLoS One. 2012; 7(12):e51952.
    View in: PubMed
    Score: 0,103
  16. Construction of effective inverted repeat silencing constructs using sodium bisulfite treatment coupled with strand-specific PCR. Biotechniques. 2012 Apr; 52(4):254-62.
    View in: PubMed
    Score: 0,098
  17. Efficient silencing of hepatitis B virus by helper-dependent adenovirus vector-mediated delivery of artificial antiviral primary micro RNAs. Microrna. 2012; 1(1):19-25.
    View in: PubMed
    Score: 0,096
  18. Efficient silencing of gene expression with modular trimeric Pol II expression cassettes comprising microRNA shuttles. Nucleic Acids Res. 2009 Jul; 37(13):e91.
    View in: PubMed
    Score: 0,080
  19. Hepatic delivery of RNA interference activators for therapeutic application. Curr Gene Ther. 2009 Apr; 9(2):91-103.
    View in: PubMed
    Score: 0,079
  20. Effective anti-hepatitis B virus hammerhead ribozymes derived from multimeric precursors. Oligonucleotides. 2007; 17(1):104-12.
    View in: PubMed
    Score: 0,068
  21. Silencing of HIV-1 subtype C primary isolates by expressed small hairpin RNAs targeted to gag. AIDS Res Hum Retroviruses. 2006 May; 22(5):401-10.
    View in: PubMed
    Score: 0,065
  22. Effective inhibition of HBV replication in vivo by anti-HBx short hairpin RNAs. Mol Ther. 2006 Feb; 13(2):411-21.
    View in: PubMed
    Score: 0,063
  23. Adenoviral Vectors: Potential as Anti-HBV Vaccines and Therapeutics. Genes (Basel). 2022 10 25; 13(11).
    View in: PubMed
    Score: 0,051
  24. Advances in designing Adeno-associated viral vectors for development of anti-HBV gene therapeutics. Virol J. 2021 12 13; 18(1):247.
    View in: PubMed
    Score: 0,048
  25. In Vivo Modelling of Hepatitis B Virus Subgenotype A1 Replication Using Adeno-Associated Viral Vectors. Viruses. 2021 11 09; 13(11).
    View in: PubMed
    Score: 0,048
  26. Hammerhead ribozyme-mediated inhibition of hepatitis B virus X gene expression in cultured cells. J Hepatol. 2000 Jul; 33(1):142-51.
    View in: PubMed
    Score: 0,043
  27. In situ demonstration of inhibitory effects of hammerhead ribozymes that are targeted to the hepatitis Bx sequence in cultured cells. Biochem Biophys Res Commun. 2000 Feb 24; 268(3):728-33.
    View in: PubMed
    Score: 0,042
  28. In vitro and in vivo hepatoma cell-specific expression of a gene transferred with an adenoviral vector. Hum Gene Ther. 1996 Aug 20; 7(13):1503-14.
    View in: PubMed
    Score: 0,033
  29. In vivo bioimaging with tissue-specific transcription factor activated luciferase reporters. Sci Rep. 2015 Jul 03; 5:11842.
    View in: PubMed
    Score: 0,031
  30. Deriving four functional anti-HIV siRNAs from a single Pol III-generated transcript comprising two adjacent long hairpin RNA precursors. Nucleic Acids Res. 2010 Oct; 38(19):6652-63.
    View in: PubMed
    Score: 0,022
  31. Effective Pol III-expressed long hairpin RNAs targeted to multiple unique sites of HIV-1. Methods Mol Biol. 2010; 629:159-74.
    View in: PubMed
    Score: 0,021
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.